Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

After Berkshire Bought Teva Pharmaceutical Stock, Should Others Follow Suit?

By Chris Lau, InvestorPlace Contributor

TEVA stock has multiple headwinds, including high debt and weakeneing Copaxone sales. But TEVA should benefit from promising new products.

Why It Is About Time That Take-Two Stock Bounces Back

By Chris Lau, InvestorPlace Contributor

The Street is undervaluing the value of TTWO's games and of Take-Two stock. TTWO looks poised to bounce back in 2020.

Hot Growth Ahead for LPSN Stock in 2019

By Chris Lau, InvestorPlace Contributor

LivePerson shares are at a yearly high and shows no sign of pulling back. Why are investors buying up LPSN stock?

Invitae Stock Is Hot Right Now And Here’s Why It Will Only Get Hotter

By Chris Lau, InvestorPlace Contributor

Even after issuing shares, NVTA stock is in high demand as the genetic testing firm reported a strong quarter

Reasons to Buy Fitbit Stock If It Dips

By Chris Lau, InvestorPlace Contributor

Fitbit reported slightly lower revenue declines and solid cost control. Why is FIT stock worth another look? It's the smartwatches.

Live-Stream Social Media Is Hot and So Is YY Stock

By Chris Lau, InvestorPlace Contributor

YY reported strong fourth-quarter revenue and earnings. YY stock should be boosted by several positive catalysts..

The Run-Up in Altria Stock Isn’t Over Yet

By Chris Lau, InvestorPlace Contributor

Investors in Altria Group (NYSE:MO) enjoyed months of steady upside throughout much of last year, only to see the stock fall since November. But on…

The Roche Merger Will Do Wonders for Spark Stock

By Chris Lau, InvestorPlace Contributor

As Spark Therapeutics gets acquired, existing shareholders, and Roche investors, will need to eveluate the merits of the deal.

Why Amazon Stock Will Break Out of Its Trading Range

By Chris Lau, InvestorPlace Contributor

Amazon.com stock is in a holding pattern despite the company finishing the holiday quarter on a strong note. Shares are set to break out.

3 Life Sciences Stocks to Invest In

By Chris Lau, InvestorPlace Contributor

Generic drug companies are on discount for investors who want to buy life sciences stocks. Why, and when will this sector recover?

Load More